iTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Michel Detheux Sells 43,883 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,883 shares of the stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $10.02, for a total value of $439,707.66. Following the completion of the sale, the chief executive officer now owns 153,903 shares of the company's stock, valued at $1,542,108.06. The trade was a 22.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michel Detheux also recently made the following trade(s):

• On Monday, June 9th, Michel Detheux sold 43,882 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.03, for a total value of $440,136.46.
• On Monday, June 9th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.03, for a total transaction of $84,252.00.
• On Friday, June 6th, Michel Detheux sold 43,882 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total transaction of $448,035.22.
• On Friday, June 6th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total transaction of $85,764.00.
• On Wednesday, June 4th, Michel Detheux sold 43,883 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $443,218.30.
• On Wednesday, June 4th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $84,840.00.

iTeos Therapeutics Price Performance

Shares of ITOS stock traded down $0.02 on Thursday, reaching $9.98. 668,533 shares of the company were exchanged, compared to its average volume of 667,026. The company has a market cap of $381.97 million, a price-to-earnings ratio of -3.17 and a beta of 1.51. The company has a 50-day moving average of $7.64 and a 200-day moving average of $7.51. iTeos Therapeutics, Inc. has a one year low of $4.80 and a one year high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.14. As a group, sell-side analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

Institutional Investors Weigh In On iTeos Therapeutics

Several large investors have recently modified their holdings of the stock. SG Americas Securities LLC grew its stake in iTeos Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock valued at $106,000 after buying an additional 1,508 shares in the last quarter. Wells Fargo & Company MN lifted its stake in iTeos Therapeutics by 16.9% in the fourth quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock worth $128,000 after purchasing an additional 2,402 shares during the last quarter. Virtus ETF Advisers LLC raised its stake in shares of iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after acquiring an additional 3,293 shares during the last quarter. Empowered Funds LLC raised its stake in shares of iTeos Therapeutics by 5.0% during the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock valued at $530,000 after acquiring an additional 3,305 shares during the last quarter. Finally, Bridgeway Capital Management LLC raised its stake in iTeos Therapeutics by 5.0% in the fourth quarter. Bridgeway Capital Management LLC now owns 69,072 shares of the company's stock worth $530,000 after buying an additional 3,305 shares in the last quarter. Hedge funds and other institutional investors own 97.16% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Piper Sandler reaffirmed an "overweight" rating and set a $12.00 price target (down previously from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Wedbush cut shares of iTeos Therapeutics from an "outperform" rating to a "neutral" rating and upped their price target for the company from $10.00 to $12.00 in a research report on Wednesday, May 28th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $12.00 price target (down previously from $13.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 28th. Leerink Partners reaffirmed a "market perform" rating and set a $9.00 price target (down previously from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, Raymond James set a $12.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $15.86.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.